dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Chen, Stephanie |
dc.contributor.author | Miravitlles Fernández, Marc |
dc.contributor.author | Rhee, Chin Kook |
dc.contributor.author | Pavord, Ian |
dc.contributor.author | Jones, Rupert |
dc.contributor.author | Carter, Victoria |
dc.date.accessioned | 2022-11-14T12:11:26Z |
dc.date.available | 2022-11-14T12:11:26Z |
dc.date.issued | 2022-09-09 |
dc.identifier.citation | Chen S, Miravitlles M, Rhee CK, Pavord ID, Jones R, Carter V, et al. Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Int J Chron Obstruct Pulmon Dis. 2022 Sep 9;17:2187–200. |
dc.identifier.issn | 1178-2005 |
dc.identifier.uri | https://hdl.handle.net/11351/8462 |
dc.description | Càrrega de malaltia; Eosinòfils; Exacerbacions |
dc.description.sponsorship | This study was funded by AstraZeneca. |
dc.language.iso | eng |
dc.publisher | Dove Medical Press |
dc.relation.ispartofseries | International Journal of Chronic Obstructive Pulmonary Disease;17 |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Malalties obstructives - Tractament |
dc.subject | Eosinofília - Tractament |
dc.subject | Teràpia respiratòria |
dc.subject.mesh | Pulmonary Disease, Chronic Obstructive |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Eosinophilia |
dc.subject.mesh | Administration, Inhalation |
dc.title | Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2147/COPD.S378649 |
dc.subject.decs | enfermedad pulmonar obstructiva crónica |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | eosinofilia |
dc.subject.decs | administración por inhalación |
dc.relation.publishversion | https://doi.org/10.2147/COPD.S378649 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Chen S] BioPharmaceuticals Medical, Respiratory & Immunology, AstraZeneca, Gaithersburg, MD, USA. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. [Rhee CK] College of Medicine, Seoul St Mary’s Hospital, the Catholic University of Korea, Seoul, South Korea. [Pavord ID] Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK. [Jones R] Faculty of Health, University of Plymouth, Plymouth, UK. [Carter V] Observational and Pragmatic Research Institute, Singapore, Singapore |
dc.identifier.pmid | 36110306 |
dc.identifier.wos | 000854022200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |